Incyte (INCY) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
August 3, 2021 7:00 AM EDT- Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020)
- Jakafi® (ruxolitinib) revenues of $529 million in Q2 2021 (+12% vs Q2 2020)
- Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
- Phase 3 TRuE-V1 and TRuE-V2 studies evaluating ruxolitinib cream in vitiligo met primary and key secondary endpoints
Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY)... More
